Factor H autoantibodies in membranoproliferative glomerulonephritis

Molecular Immunology

Volumn 52, Issue 3-4, 2012, Pages 200-206

  Goodship, Timothy H J ^a   Pappworth, Isabel Y ^a   Toth, Tibor ^b   Denton, Mark ^c   Houlberg, Kris ^d   McCormick, Frances ^d   Warland, David ^e   Moore, Iain ^a   Hunze, Eva Maria ^a   Staniforth, Scott J ^a   Hayes, Christine ^a   Cavalcante, Danielle Paixão ^f   Kavanagh, David ^a   Strain, Lisa ^g   Herbert, Andrew P ^h   Schmidt, Christoph Q ^h   Barlow, Paul N ^h   Harris, Claire L ^f   Marchbank, Kevin J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

^c MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^d DERRIFORD HOSPITAL   (United Kingdom)

^e DORSET COUNTY HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^f CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^g NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^h UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Autoantibodies; Complement; Factor H; MPGN

Indexed keywords

AUTOANTIBODY; FACTOR H AUTOANTIBODY; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BINDING SITE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE DOSAGE; HEMOLYSIS; HUMAN; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; NONHUMAN; NUCLEOTIDE REPEAT; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; SHORT CONSENSUS REPEAT;

ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; BINDING SITES, ANTIBODY; COMPLEMENT C3; COMPLEMENT C3 NEPHRITIC FACTOR; COMPLEMENT FACTOR H; FEMALE; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

ORYCTOLAGUS CUNICULUS;

EID: 84862301748     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2012.05.009     Document Type: Article

References (41)

1. Alchi B., Jayne D. Membranoproliferative glomerulonephritis. Pediatric Nephrology 2010, 25:1409-1418.
2. Appel G.B., Cook H.T., Hageman G., Jennette J.C., Kashgarian M., Kirschfink M., Lambris J.D., Lanning L., Lutz H.U., Meri S., Rose N.R., Salant D.J., Sethi S., Smith R.J., Smoyer W., Tully H.F., Tully S.P., Walker P., Welsh M., Wurzner R., Zipfel P.F. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. Journal of the American Society of Nephrology 2005, 16:1392-1403.
3. Brackman D., Sartz L., Leh S., Kristoffersson A.C., Bjerre A., Tati R., Fremeaux-Bacchi V., Karpman D. Thrombotic microangiopathy mimicking membranoproliferative glomerulonephritis. Nephrology, Dialysis, Transplantation 2011, 26:3399-3403.
4. Chen Q., Muller D., Rudolph B., Hartmann A., Kuwertz-Broking E., Wu K., Kirschfink M., Skerka C., Zipfel P.F. Combined C3b and factor B autoantibodies and MPGN type II. New England Journal of Medicine 2011, 365:2340-2342.
5. Davis A.E., Ziegler J.B., Gelfand E.W., Rosen F.S., Alper C.A. Heterogeneity of nephritic factor and its identification as an immunoglobulin. Proceedings of the National Academy of Sciences of the United States of America 1977, 74:3980-3983.
6. Dhillon B., Wright A.F., Tufail A., Pappworth I., Hayward C., Moore I., Strain L., Kavanagh D., Barlow P., Herbert A.P., Schmidt C.Q., Armbrecht A.M., Laude A., Deary I.J., Staniforth S.J., Holmes L.V., Goodship T.H.J., Marchbank K.J. Complement factor H autoantibodies and age-related macular degeneration. Investigative Ophthalmology and Visual Science 2010.
7. Dragon-Durey M.A., Loirat C., Cloarec S., Macher M.A., Blouin J., Nivet H., Weiss L., Fridman W.H., Fremeaux-Bacchi V. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. Journal of the American Society of Nephrology 2005, 16:555-563.
8. Dragon-Durey M.A., Sethi S.K., Bagga A., Blanc C., Blouin J., Ranchin B., Andre J.L., Takagi N., Cheong H.I., Hari P., Le Quintrec M., Niaudet P., Loirat C., Fridman W.H., Fremeaux-Bacchi V. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. Journal of the American Society of Nephrology 2010, 21:2180-2187.
9. Ferreira V.P., Herbert A.P., Cortes C., McKee K.A., Blaum B.S., Esswein S.T., Uhrin D., Barlow P.N., Pangburn M.K., Kavanagh D. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. Journal of Immunology 2009, 182:7009-7018.
10. Fremeaux-Bacchi V., Miller E.C., Liszewski M.K., Strain L., Blouin J., Brown A.L., Moghal N., Kaplan B.S., Weiss R.A., Lhotta K., Kapur G., Mattoo T., Nivet H., Wong W., Gie S., Hurault de Ligny B., Fischbach M., Gupta R., Hauhart R., Meunier V., Loirat C., Dragon-Durey M.A., Fridman W.H., Janssen B.J., Goodship T.H.J., Atkinson J.P. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008, 112:4948-4952.
11. Gale D.P., de Jorge E.G., Cook H.T., Martinez-Barricarte R., Hadjisavvas A., McLean A.G., Pusey C.D., Pierides A., Kyriacou K., Athanasiou Y., Voskarides K., Deltas C., Palmer A., Fremeaux-Bacchi V., de Cordoba S.R., Maxwell P.H., Pickering M.C. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 2010, 376:794-801.
12. Jokiranta T.S., Solomon A., Pangburn M.K., Zipfel P.F., Meri S. Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. Journal of Immunology 1999, 163:4590-4596.
13. Jozsi M., Licht C., Strobel S., Zipfel S.L., Richter H., Heinen S., Zipfel P.F., Skerka C. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008, 111:1512-1514.
14. Jozsi M., Strobel S., Dahse H.M., Liu W.S., Hoyer P.F., Oppermann M., Skerka C., Zipfel P.F. Anti-factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 2007, 110:1516-1518.
15. Kavanagh D., Kemp E.J., Mayland E., Winney R.J., Duffield J.S., Warwick G., Richards A., Ward R., Goodship J.A., Goodship T.H. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. Journal of the American Society of Nephrology 2005, 16:2150-2155.
16. Kavanagh D., Kemp E.J., Richards A., Burgess R.M., Mayland E., Goodship J.A., Goodship T.H. Does complement factor B have a role in the pathogenesis of atypical HUS?. Molecular Immunology 2006, 43:856-859.
17. Leroy V., Fremeaux-Bacchi V., Peuchmaur M., Baudouin V., Deschenes G., Macher M.A., Loirat C. Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation. Pediatric Nephrology 2011, 26:419-424.
18. Licht C., Fremeaux-Bacchi V. Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis. Thrombosis and Haemostasis 2009, 101:271-278.
19. Licht C., Heinen S., Jozsi M., Loschmann I., Saunders R.E., Perkins S.J., Waldherr R., Skerka C., Kirschfink M., Hoppe B., Zipfel P.F. Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney International 2006, 70:42-50.
20. Licht C., Schlotzer-Schrehardt U., Kirschfink M., Zipfel P.F., Hoppe B. MPGN II - genetically determined by defective complement regulation?. Pediatric Nephrology 2007, 22:2-9.
21. Lorcy N., Rioux-Leclercq N., Lombard M.L., Le Pogamp P., Vigneau C. Three kidneys, two diseases, one antibody?. Nephrology, Dialysis, Transplantation 2011, 26:3811-3813.
22. Martinez-Barricarte R., Heurich M., Valdes-Canedo F., Vazquez-Martul E., Torreira E., Montes T., Tortajada A., Pinto S., Lopez-Trascasa M., Morgan B.P., Llorca O., Harris C.L., Rodriguez de Cordoba S. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. Journal of Clinical Investigation 2010, 120:3702-3712.
23. Meri S., Koistinen V., Miettinen A., Tornroth T., Seppala I.J. Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis. Journal of Experimental Medicine 1992, 175:939-950.
24. Moore I., Strain L., Pappworth I., Kavanagh D., Barlow P.N., Herbert A.P., Schmidt C.Q., Staniforth S.J., Holmes L.V., Ward R., Morgan L., Goodship T.H.J., Marchbank K.J. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4 and with mutations in CFH, CFI, CD46, and C3 in patients with atypical haemolytic uraemic syndrome. Blood 2010, 115:379-387.
25. Pickering M.C., Cook H.T. Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clinical and Experimental Immunology 2008, 151:210-230.
26. Richards A., Buddles M.R., Donne R.L., Kaplan B.S., Kirk E., Venning M.C., Tielemans C.L., Goodship J.A., Goodship T.H.J. Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. American Journal of Human Genetics 2001, 68:485-490.
27. Richards A., Kemp E.J., Liszewski M.K., Goodship J.A., Lampe A.K., Decorte R., Muslumanoglu M.H., Kavukcu S., Filler G., Pirson Y., Wen L.S., Atkinson J.P., Goodship T.H.J. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:12966-12971.
28. Rother U. A new screening test for C3 nephritis factor based on a stable cell bound convertase on sheep erythrocytes. Journal of Immunological Methods 1982, 51:101-107.
29. Saunders R.E., Goodship T.H.J., Zipfel P.F., Perkins S.J. An interactive web database of factor H-associated hemolytic uremic syndrome mutations: insights into the structural consequences of disease-associated mutations. Human Mutation 2006, 27:21-30.
30. Schmidt C.Q., Herbert A.P., Kavanagh D., Gandy C., Fenton C.J., Blaum B.S., Lyon M., Uhrin D., Barlow P.N. A new map of glycosaminoglycan and C3b binding sites on factor H. Journal of Immunology 2008, 181:2610-2619.
31. Schouten J.P., McElgunn C.J., Waaijer R., Zwijnenburg D., Diepvens F., Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Research 2002, 30:e57.
32. Servais A., Fremeaux-Bacchi V., Lequintrec M., Salomon R., Blouin J., Knebelmann B., Grunfeld J.P., Lesavre P., Noel L.H., Fakhouri F. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with hemolytic uremic syndrome. Journal of Medical Genetics 2007, 44:193-199.
33. Sethi S., Fervenza F.C., Zhang Y., Nasr S.H., Leung N., Vrana J., Cramer C., Nester C.M., Smith R.J. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clinical Journal of the American Society of Nephrology 2011, 6:1009-1017.
34. Smith R.J., Alexander J., Barlow P.N., Botto M., Cassavant T.L., Cook H.T., de Cordoba S.R., Hageman G.S., Jokiranta T.S., Kimberling W.J., Lambris J.D., Lanning L.D., Levidiotis V., Licht C., Lutz H.U., Meri S., Pickering M.C., Quigg R.J., Rops A.L., Salant D.J., Sethi S., Thurman J.M., Tully H.F., Tully S.P., van der Vlag J., Walker P.D., Wurzner R., Zipfel P.F. New approaches to the treatment of dense deposit disease. Journal of the American Society of Nephrology 2007, 18:2447-2456.
35. Spitzer R.E., Stitzel A.E., Tsokos G. On the origin of C3 nephritic factor (antibody to the alternative pathway C3 convertase): evidence for the Adam and Eve concept of autoantibody production. Clinical Immunology and Immunopathology 1992, 64:177-183.
36. Spitzer R.E., Vallota E.H., Forristal J., Sudora E., Stitzel A., Davis N.C., West C.D. Serum C3 lytic system in patients with glomerulonephritis. Science 1969, 164:436-437.
37. Strife C.F., Jackson E.C., McAdams A.J. Type III membranoproliferative glomerulonephritis: long-term clinical and morphologic evaluation. Clinical Nephrology 1984, 21:323-334.
38. Strobel S., Zimmering M., Papp K., Prechl J., Jozsi M. Anti-factor B autoantibody in dense deposit disease. Molecular Immunology 2010, 47:1476-1483.
39. Walker P.D., Ferrario F., Joh K., Bonsib S.M. Dense deposit disease is not a membranoproliferative glomerulonephritis. Modern Pathology 2007, 20:605-616.
40. West C.D. Idiopathic membranoproliferative glomerulonephritis in childhood. Pediatric Nephrology 1992, 6:96-103.
41. West C.D. Complement and glomerular disease. The Human Complement System in Health and Diseases 1998, 571-596. Marcel Dekker Inc., New York. J.E. Volanakis, M.M. Frank (Eds.).